NASDAQ:EDGE - Edge Therapeutics Stock Price, Price Target & More

$1.15 -0.04 (-3.36 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$1.19
Today's Range$1.15 - $1.19
52-Week Range$0.95 - $17.77
Volume611,752 shs
Average Volume1.25 million shs
Market Capitalization$38.59 million
P/E Ratio-0.69
Dividend YieldN/A
Beta3.98

About Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics logoEdge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Receive EDGE News and Ratings via Email

Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDGE
CUSIPN/A
Phone800-208-3343

Debt

Debt-to-Equity Ratio0.28%
Current Ratio6.92%
Quick Ratio6.92%

Price-To-Earnings

Trailing P/E Ratio-0.69
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.02 per share
Price / Book0.57

Profitability

EPS (Most Recent Fiscal Year)($1.67)
Net Income$-50,850,000.00
Net MarginsN/A
Return on Equity-67.83%
Return on Assets-50.02%

Miscellaneous

Employees38
Outstanding Shares30,870,000

How to Become a New Pot Stock Millionaire

Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics (NASDAQ:EDGE) issued its earnings results on Thursday, March, 1st. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.02. View Edge Therapeutics' Earnings History.

When is Edge Therapeutics' next earnings date?

Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Edge Therapeutics.

What price target have analysts set for EDGE?

2 Wall Street analysts have issued 1-year price targets for Edge Therapeutics' shares. Their forecasts range from $17.00 to $17.00. On average, they anticipate Edge Therapeutics' stock price to reach $17.00 in the next twelve months. View Analyst Ratings for Edge Therapeutics.

Are investors shorting Edge Therapeutics?

Edge Therapeutics saw a increase in short interest in April. As of April 13th, there was short interest totalling 1,493,401 shares, an increase of 42.2% from the March 30th total of 1,050,090 shares. Based on an average trading volume of 2,685,515 shares, the days-to-cover ratio is presently 0.6 days. Currently, 7.2% of the company's stock are short sold.

Who are some of Edge Therapeutics' key competitors?

Who are Edge Therapeutics' key executives?

Edge Therapeutics' management team includes the folowing people:
  • Mr. Brian A. Leuthner, Co-Founder, Chief Exec. Officer, Pres and Director (Age 53)
  • Dr. R. Loch MacDonald M.D., Ph.D., Co-Founder, Chief Scientific Officer and Director (Age 56)
  • Dr. Herbert J. Faleck D.O., Chief Medical Officer (Age 65)
  • Mr. Andrew Saik, Chief Financial Officer (Age 49)
  • Mr. Daniel Brennan, Chief Operating Officer (Age 50)

Has Edge Therapeutics been receiving favorable news coverage?

Media stories about EDGE stock have been trending positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edge Therapeutics earned a coverage optimism score of 0.29 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.18 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Edge Therapeutics?

Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edge Therapeutics' stock price today?

One share of EDGE stock can currently be purchased for approximately $1.15.

How big of a company is Edge Therapeutics?

Edge Therapeutics has a market capitalization of $38.59 million. The biotechnology company earns $-50,850,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. Edge Therapeutics employs 38 workers across the globe.

How can I contact Edge Therapeutics?

Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]


MarketBeat Community Rating for Edge Therapeutics (EDGE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Edge Therapeutics (NASDAQ:EDGE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Edge Therapeutics in the last 12 months. Their average twelve-month price target is $17.00, suggesting that the stock has a possible upside of 1,378.26%. The high price target for EDGE is $17.00 and the low price target for EDGE is $17.00. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 1.503.002.672.50
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.00$17.00$22.6667$25.50
Price Target Upside: 1,378.26% upside59.47% upside112.63% upside171.28% upside

Edge Therapeutics (NASDAQ:EDGE) Consensus Price Target History

Price Target History for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ:EDGE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Credit Suisse GroupDowngradeOutperform -> Underperform$17.00HighView Rating Details
3/28/2018JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
3/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$21.00N/AView Rating Details
3/3/2017GuggenheimReiterated RatingBuy -> In-Line$30.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Edge Therapeutics (NASDAQ:EDGE) Earnings History and Estimates Chart

Earnings by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ:EDGE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.53)($0.53)($0.53)
Q2 20181($0.52)($0.52)($0.52)
Q3 20181($0.51)($0.51)($0.51)
Q4 20181($0.54)($0.54)($0.54)

Edge Therapeutics (NASDAQ EDGE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($0.55)N/AView Earnings Details
3/1/2018Q4 2017($0.43)($0.45)ViewListenView Earnings Details
11/1/2017Q3 2017($0.48)($0.37)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.4370)($0.44)ViewListenView Earnings Details
5/3/2017Q1 2017($0.4230)($0.42)ViewListenView Earnings Details
3/2/2017Q4 2016($0.42)($0.33)ViewListenView Earnings Details
11/1/2016Q3 2016($0.38)($0.37)ViewN/AView Earnings Details
8/3/2016Q2($0.38)($0.33)ViewListenView Earnings Details
5/3/2016Q1 2016($0.34)($0.32)ViewListenView Earnings Details
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Edge Therapeutics (NASDAQ:EDGE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Edge Therapeutics (NASDAQ EDGE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 36.19%
Institutional Ownership Percentage: 48.74%
Insider Trading History for Edge Therapeutics (NASDAQ:EDGE)
Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ EDGE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/21/2018R. Loch MacdonaldInsiderSell2,500$16.52$41,300.00580,602View SEC Filing  
3/19/2018R. Loch MacdonaldInsiderSell2,500$16.66$41,650.00580,602View SEC Filing  
3/1/2018Brian A LeuthnerCEOSell2,500$14.81$37,025.0072,736View SEC Filing  
2/22/2018R. Loch MacdonaldInsiderSell2,500$14.49$36,225.00590,602View SEC Filing  
2/20/2018R. Loch MacdonaldInsiderSell5,000$13.75$68,750.00590,602View SEC Filing  
2/1/2018Brian A LeuthnerCEOSell2,500$13.14$32,850.0082,736View SEC Filing  
1/3/2018Brian A LeuthnerInsiderSell5,000$10.11$50,550.0087,736View SEC Filing  
12/5/2017Brian A LeuthnerInsiderSell7,500$9.86$73,950.0095,236View SEC Filing  
12/1/2017Brian A LeuthnerCEOSell2,500$9.92$24,800.0095,236View SEC Filing  
11/22/2017Albert N. Marchio IIInsiderSell3,361$10.00$33,610.00View SEC Filing  
11/3/2017Brian A LeuthnerInsiderSell7,500$10.91$81,825.00102,736View SEC Filing  
11/1/2017Brian A LeuthnerCEOSell2,500$10.92$27,300.00102,736View SEC Filing  
10/4/2017Brian A LeuthnerInsiderSell7,500$10.96$82,200.00View SEC Filing  
10/3/2017Brian A LeuthnerCEOSell2,500$10.93$27,325.00110,236View SEC Filing  
10/2/2017Brian A LeuthnerCEOSell2,500$10.81$27,025.00110,236View SEC Filing  
9/6/2017Brian A LeuthnerInsiderSell7,500$10.21$76,575.00117,736View SEC Filing  
9/5/2017Brian A LeuthnerCEOSell2,500$9.94$24,850.00117,736View SEC Filing  
9/1/2017Brian A LeuthnerCEOSell2,500$10.37$25,925.00117,736View SEC Filing  
8/29/2017Albert N Marchio IIInsiderSell2,500$10.42$26,050.003,361View SEC Filing  
8/23/2017Albert N Marchio IIInsiderSell1,000$10.39$10,390.005,861View SEC Filing  
8/3/2017Brian A LeuthnerInsiderSell7,500$10.53$78,975.00125,236View SEC Filing  
7/6/2017Brian A LeuthnerInsiderSell7,500$10.19$76,425.00132,736View SEC Filing  
3/6/2017James J LoughlinDirectorBuy3,000$9.24$27,720.0019,625View SEC Filing  
2/7/2017Brian A LeuthnerInsiderSell1,500$9.52$14,280.00245,479View SEC Filing  
2/6/2017Brian A LeuthnerInsiderSell3,000$9.61$28,830.00248,479View SEC Filing  
2/2/2017Brian A LeuthnerInsiderSell3,000$9.50$28,500.00251,479View SEC Filing  
12/1/2016Brian A LeuthnerInsiderSell7,500$11.60$87,000.00252,979View SEC Filing  
10/3/2016Brian A LeuthnerInsiderSell7,500$10.25$76,875.00260,479View SEC Filing  
8/8/2016W Bradford MiddlekauffVPBuy10,000$9.48$94,800.009,857View SEC Filing  
8/1/2016Brian A LeuthnerInsiderSell7,500$9.54$71,550.00267,979View SEC Filing  
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.0041,656View SEC Filing  
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Edge Therapeutics (NASDAQ EDGE) News Headlines

Source:
DateHeadline
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Edge Therapeutics, Inc. -- EDGEINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors Edge Therapeutics, Inc. -- EDGE
www.businesswire.com - April 25 at 4:48 PM
Edge Shareholder Alert: Bernstein Liebhard LLP Announces That A Class Action Lawsuit Has Been Filed Against Edge Therapeutics, Inc. - EDGEEdge Shareholder Alert: Bernstein Liebhard LLP Announces That A Class Action Lawsuit Has Been Filed Against Edge Therapeutics, Inc. - EDGE
www.bizjournals.com - April 25 at 4:48 PM
INVESTOR ALERT: Kirby McInerney LLP Announces a Securities Class Action on Behalf of Edge Therapeutics, Inc. InvestorsINVESTOR ALERT: Kirby McInerney LLP Announces a Securities Class Action on Behalf of Edge Therapeutics, Inc. Investors
finance.yahoo.com - April 24 at 4:52 PM
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Edge Therapeutics, Inc. Investors (EDGE)Glancy Prongay & Murray LLP Continues Investigation on Behalf of Edge Therapeutics, Inc. Investors (EDGE)
www.bizjournals.com - April 24 at 9:11 AM
Edge Therapeutics (EDGE) Set to Announce Earnings on TuesdayEdge Therapeutics (EDGE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - April 24 at 8:04 AM
BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast CancerBriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
globenewswire.com - April 23 at 8:58 AM
EDGE INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Edge Therapeutics, Inc. InvestorsEDGE INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Edge Therapeutics, Inc. Investors
finance.yahoo.com - April 16 at 4:36 PM
Edge Therapeutics (EDGE) Upgraded at BidaskClubEdge Therapeutics (EDGE) Upgraded at BidaskClub
www.americanbankingnews.com - April 13 at 4:54 PM
BidaskClub Lowers Edge Therapeutics (EDGE) to HoldBidaskClub Lowers Edge Therapeutics (EDGE) to Hold
www.americanbankingnews.com - April 10 at 3:54 PM
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OKs AMGN Drug Label ExpansionBiotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
finance.yahoo.com - April 4 at 4:49 PM
Edge Therapeutics Loses Edge on Failure of Late-Stage StudyEdge Therapeutics Loses Edge on Failure of Late-Stage Study
www.zacks.com - April 2 at 9:43 AM
Edge Therapeutics (EDGE) Stock Rating Lowered by Zacks Investment ResearchEdge Therapeutics (EDGE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 31 at 12:32 PM
Form 4 Edge Therapeutics, Inc. For: Mar 23 Filed by: Conti Kurt GForm 4 Edge Therapeutics, Inc. For: Mar 23 Filed by: Conti Kurt G
www.streetinsider.com - March 31 at 9:09 AM
Edge Therapeutics (EDGE) Downgraded by BidaskClubEdge Therapeutics (EDGE) Downgraded by BidaskClub
www.americanbankingnews.com - March 30 at 1:07 PM
Credit Suisse Slashes Edge Therapeutics Price Target By 94%, Downgrades Stock After Failed TrialCredit Suisse Slashes Edge Therapeutics Price Target By 94%, Downgrades Stock After Failed Trial
finance.yahoo.com - March 29 at 4:39 PM
Investor Alert: Kaplan Fox Announces Investigation Of Edge Therapeutics, Inc.Investor Alert: Kaplan Fox Announces Investigation Of Edge Therapeutics, Inc.
finance.yahoo.com - March 29 at 4:39 PM
Edge Therapeutics (EDGE) Lowered to "Underperform" at Credit Suisse GroupEdge Therapeutics (EDGE) Lowered to "Underperform" at Credit Suisse Group
www.americanbankingnews.com - March 29 at 12:28 PM
Why Tesla, Amazon.com, and Edge Therapeutics Slumped TodayWhy Tesla, Amazon.com, and Edge Therapeutics Slumped Today
finance.yahoo.com - March 29 at 9:36 AM
Edge Therapeutics (EDGE) Says DMC Recommended Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage be StoppedEdge Therapeutics (EDGE) Says DMC Recommended Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage be Stopped
www.streetinsider.com - March 28 at 4:37 PM
Heres Why Edge Therapeutics Stock Collapsed TodayHere's Why Edge Therapeutics Stock Collapsed Today
www.msn.com - March 28 at 4:37 PM
Why Edge Therapeutics Fell Off the Edge of the EarthWhy Edge Therapeutics Fell Off the Edge of the Earth
247wallst.com - March 28 at 4:37 PM
Here's Why Edge Therapeutics Stock Collapsed TodayHere's Why Edge Therapeutics Stock Collapsed Today
finance.yahoo.com - March 28 at 4:37 PM
Edge Therapeutics (EDGE) Downgraded by JMP SecuritiesEdge Therapeutics (EDGE) Downgraded by JMP Securities
www.americanbankingnews.com - March 28 at 11:27 AM
 Edge Therapeutics Inc (EDGE) Receives Consensus Recommendation of "Strong Buy" from Analysts Edge Therapeutics Inc (EDGE) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 28 at 9:45 AM
Edge Therapeutics bails on late-stage study of lead candidate EG-1962, job cuts plannedEdge Therapeutics bails on late-stage study of lead candidate EG-1962, job cuts planned
seekingalpha.com - March 28 at 9:29 AM
Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid HemorrhageEdge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
finance.yahoo.com - March 28 at 9:29 AM
Edge Therapeuticss stock plummets on heavy volume after late-stage drug trial discontinuedEdge Therapeutics's stock plummets on heavy volume after late-stage drug trial discontinued
finance.yahoo.com - March 28 at 9:29 AM
Edge Therapeutics (EDGE) Raised to Buy at BidaskClubEdge Therapeutics (EDGE) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 25 at 3:12 PM
Edge Therapeutics Inc (EDGE) Insider R. Loch Macdonald Sells 2,500 SharesEdge Therapeutics Inc (EDGE) Insider R. Loch Macdonald Sells 2,500 Shares
www.americanbankingnews.com - March 21 at 1:27 PM
R. Loch Macdonald Sells 2,500 Shares of Edge Therapeutics Inc (EDGE) StockR. Loch Macdonald Sells 2,500 Shares of Edge Therapeutics Inc (EDGE) Stock
www.americanbankingnews.com - March 21 at 1:26 PM
Zacks: Edge Therapeutics Inc (EDGE) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Edge Therapeutics Inc (EDGE) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 18 at 9:12 PM
Edited Transcript of EDGE earnings conference call or presentation 1-Mar-18 1:30pm GMTEdited Transcript of EDGE earnings conference call or presentation 1-Mar-18 1:30pm GMT
finance.yahoo.com - March 18 at 9:10 AM
Comparing Vaxart (VXRT) & Edge Therapeutics (EDGE)Comparing Vaxart (VXRT) & Edge Therapeutics (EDGE)
www.americanbankingnews.com - March 15 at 1:48 PM
Edge Therapeutics (EDGE) Lifted to "Strong-Buy" at BidaskClubEdge Therapeutics (EDGE) Lifted to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - March 11 at 5:59 PM
Edge Therapeutics Inc (EDGE) Holdings Reduced by VHCP Management II LLCEdge Therapeutics Inc (EDGE) Holdings Reduced by VHCP Management II LLC
www.americanbankingnews.com - March 6 at 10:50 AM
Edge Therapeutics Inc (EDGE) CEO Sells $37,025.00 in StockEdge Therapeutics Inc (EDGE) CEO Sells $37,025.00 in Stock
www.americanbankingnews.com - March 5 at 9:14 AM
Q1 2018 EPS Estimates for Edge Therapeutics Inc (EDGE) Increased by AnalystQ1 2018 EPS Estimates for Edge Therapeutics Inc (EDGE) Increased by Analyst
www.americanbankingnews.com - March 5 at 2:40 AM
Edge Therapeutics (EDGE) Announces  Earnings Results, Misses Expectations By $0.02 EPSEdge Therapeutics (EDGE) Announces Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - March 2 at 10:39 AM
BRIEF-Edge Therapeutics Reports Qtrly Loss Per Share $0.45BRIEF-Edge Therapeutics Reports Qtrly Loss Per Share $0.45
www.reuters.com - March 1 at 5:00 PM
Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsEdge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 1 at 8:59 AM
Edge Therapeutics, Inc. to Host Earnings CallEdge Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 8:59 AM
When Can We Expect A Profit From Edge Therapeutics Inc (NASDAQ:EDGE)?When Can We Expect A Profit From Edge Therapeutics Inc (NASDAQ:EDGE)?
finance.yahoo.com - February 28 at 5:12 PM
Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018
finance.yahoo.com - February 26 at 9:07 AM
Applied Therapeutics Announces Support for Rare Disease Day 2018Applied Therapeutics Announces Support for Rare Disease Day 2018
www.bizjournals.com - February 23 at 5:07 PM
Edge Therapeutics Inc (EDGE) Insider Sells $36,225.00 in StockEdge Therapeutics Inc (EDGE) Insider Sells $36,225.00 in Stock
www.americanbankingnews.com - February 22 at 7:26 PM
Insider Selling: Edge Therapeutics Inc (EDGE) Insider Sells 5,000 Shares of StockInsider Selling: Edge Therapeutics Inc (EDGE) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - February 22 at 7:08 PM
Edge Therapeutics (EDGE) Scheduled to Post Earnings on WednesdayEdge Therapeutics (EDGE) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:22 AM
Zacks: Analysts Set $21.00 Target Price for Edge Therapeutics Inc (EDGE)Zacks: Analysts Set $21.00 Target Price for Edge Therapeutics Inc (EDGE)
www.americanbankingnews.com - February 19 at 7:34 AM
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
www.zacks.com - February 7 at 9:23 AM
 Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.47 Earnings Per Share Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.47 Earnings Per Share
www.americanbankingnews.com - February 4 at 1:18 AM

SEC Filings

Edge Therapeutics (NASDAQ:EDGE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Edge Therapeutics (NASDAQ:EDGE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Edge Therapeutics (NASDAQ EDGE) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.